Logo image of ALT

ALTIMMUNE INC (ALT) Stock News

NASDAQ:ALT - Nasdaq - US02155H2004 - Common Stock - Currency: USD

5.43  -0.18 (-3.21%)

After market: 5.39 -0.04 (-0.74%)

ALT Latest News, Press Relases and Analysis

News Image
10 days ago - Yahoo Finance

Could Altimmune, Inc. (ALT): Analysts See 288% Upside Potential

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Altimmune, Inc. (NASDAQ:ALT) was one of the stocks that was covered in that article. Wall Street analysts believe ALT has a 288% upside potential over the next 12 months. Altimmune, Inc.(NASDAQ:ALT) is a clinical-stage biopharmaceutical company. It focuses on developing treatments for […]

Mentions: CAPR CSCO CATX ABCL ...

News Image
11 days ago - Benzinga

Altimmune (ALT) Stock Rises Amid Clinical Trial Progress: What's Going On?

Altimmune stock rose on Tuesday without news, possibly due to high short interest. Its new trial for Alcohol Use Disorder and upcoming MASH results may be fueling excitement.

News Image
12 days ago - Altimmune, Inc

Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)

GAITHERSBURG, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel...

News Image
17 days ago - Yahoo Finance

Morning Movers: UnitedHealth sinks following CEO exit and outlook suspension

Stock futures are mixed, signaling a potential pause following Monday’s rally driven by optimism over a temporary U.S.-China trade deal. In corporate news, UnitedHealth Group shares plunged 10% after CEO Andrew Witty stepped down, with former CEO Stephen Hemsley stepping in. The company also suspended its outlook due to rising medical costs.​ Bitcoin has regained value above $103,800, aligning with Coinbase’s rise after inclusion into the S&P 500.​ In pre-market trading, S&P 500 futures were fla

Mentions: UNH COIN UAA HMC ...

News Image
17 days ago - Altimmune, Inc

Altimmune to Participate at Two Upcoming Investor Conferences

GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel...

News Image
18 days ago - Stocktwits

Altimmune Reports Better-Than-Feared Q1 Loss, Secures $100M Credit Facility: Retail’s Pleased

In the second quarter, the firm expects to announce data from a phase 2 trial of its investigational therapy, Pemvidutide, in treating metabolic dysfunction-associated steatohepatitis (MASH).

Mentions: VTI IWM

News Image
18 days ago - Altimmune, Inc

Altimmune Announces First Quarter 2025 Financial Results and Business Update

Top-line data from IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) expected in Q2 2025 Phase 2 trials in...

News Image
19 days ago - Zacks Investment Research

Will Healthy Y/Y Revenue Growth Boost Keysight's Q2 Earnings?

KEYS is expected to report year-over-year revenue growth in the second quarter of fiscal 2025, driven by healthy demand across both segments.

Mentions: STN KEYS CSWC

News Image
19 days ago - Zacks Investment Research

Doximity Q4 Earnings Likely to Reflect Strong Product Momentum

Doximity's Q4 performance likely witnessed strong product-driven gains from new modules and integrated programs, though early revenue pull-forward might have tempered sequential growth.

Mentions: HQY STOK DOCS

News Image
22 days ago - Zacks Investment Research

How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86%

The mean of analysts' price targets for Altimmune (ALT) points to a 285.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

News Image
23 days ago - Altimmune, Inc

Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™

MASH Resolution Index (MASHResInd) model highly predictive of MASH resolution...

News Image
25 days ago - Altimmune, Inc

Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025

GAITHERSBURG, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that...

News Image
a month ago - Altimmune, Inc

Altimmune to Present at Upcoming EASL International Liver Congress™ 2025

GAITHERSBURG, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing...

News Image
a month ago - Altimmune, Inc

Altimmune to Participate in the Citizens Life Sciences Conference

GAITHERSBURG, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced...

News Image
2 months ago - Yahoo Finance

Buying These Dirt-Cheap Stocks Could Be a Brilliant Move

Here's why they think Altimmune (NASDAQ: ALT), Moderna (NASDAQ: MRNA), and Pfizer (NYSE: PFE) are dirt cheap now, and why buying these value stocks could be a brilliant move. David Jagielski (Altimmune): If you want to swing for the fences, one underrated GLP-1 weight loss drug company you'll want to consider investing in right now is Altimmune. It's not the safest healthcare stock to own as there's no guarantee of how well its GLP-1 drug candidate, pemvidutide, will perform in late-stage trials, but its clinical results so far have been promising.

Mentions: PFE MRNA

News Image
2 months ago - Stocktwits

Altimmune Shares Sink This Year, But Retail Traders See A Buyout On The Horizon

A Betaville report suggested Altimmune has begun a strategic review with an adviser, with speculation that three major pharmaceutical firms may be involved.

Mentions: VTI IWM XBI NBI

News Image
3 months ago - Altimmune, Inc

Altimmune to Host Virtual R&D Day on March 13, 2025

Program to Feature Presentations from Renowned KOLs in Obesity, MASH and Two Additional Indications for Pemvidutide following recent IND Clearances by FDA...

News Image
3 months ago - Altimmune, Inc

Altimmune to Participate in the Leerink Global Healthcare Conference

GAITHERSBURG, Md., March 03, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced...

News Image
3 months ago - Altimmune, Inc

Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Top-line data from Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) to be reported in Q2 2025 ...

News Image
3 months ago - Altimmune, Inc

Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors

Ms. Lawver, former Chief Commercial Officer of Dexcom and Global Vice President at Johnson & Johnson responsible for billion-dollar Immunology and...